Many clinical studies have confirmed that sera sST2 is a powerful predictor of mortality independently and when combined with N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with HF and LV systolic dysfunction with a LVEF ≤ 45% (38–41). The gene discussed is NPPB; the disease is hydrops fetalis.